Egypt’s Migraine drug market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Migraine is a neurological condition that can cause multiple symptoms. It’s frequently characterized by intense, debilitating headaches. Symptoms may include nausea, vomiting, difficulty speaking, numbness or tingling, and sensitivity to light and sound. Migraines often run in families and affect all ages.
Females are more commonly found with migraines and therefore the female population of Egypt is likely to be the main consumer in the market. Studies show primary headache disorders have a high prevalence in Egypt and those suffering from migraine experience it of medium to high intensity.
The rate of migraine prevalence and new product launches in the market for treatment will drive the market growth up in the forecast period. More people are aware and seeking treatment for their migraines and other headache disorders. Migraines are more commonly reported in females and 50% of Egypt’s population comprises females. Thus, increased complaints among them will drive the demand for migraine drugs in the forecast period.
Low rates of migraine diagnosis or misdiagnosis could hamper the market growth.